REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly making false and misleading statements regarding the IGNYTE trial, which led to investor losses during the specified class period [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Replimune securities between November 22, 2024, and July 21, 2025, with a deadline of September 22, 2025, for investors to apply as lead plaintiffs [1]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, resulting in the FDA deeming the trial inadequate [3]. Investor Information - Investors who suffered losses or have questions regarding their rights are encouraged to contact the law firm for more information [4]. - The law firm emphasizes that there is no cost or obligation for investors to inquire about their claims [4]. Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [5].